Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Bluebird Bio's Thalassemia Gene Therapy Under Priority Review With FDA
The FDA has accepted Bluebird bio Inc's (NASDAQ: BLUE) marketing application for betibeglogene autotemcel (beti-cel) for β-thalassemia. The agency has... 
Via Benzinga
Exposures Product Safety
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
Why Bluebird Bio Stock Plunged Today
Two analysts downgraded the biotech stock. 
Via The Motley Fool
Market Rally Continues as Dow Nabs Intraday Highs
S&P 500 Index and Nasdaq Composite are sporting modest gains, with the Dow locking in another fresh intraday high. 
Via Talk Markets
Topics Stocks
Exposures US Equities
64 Biggest Movers From Yesterday
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile... 
Via Benzinga
38 Stocks Moving In Monday's Mid-Day Session
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares climbed 129.8% to $7.49 after the company announced the launch of its E-Boost portfolio of mobile Electric Vehicle... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers PetVivo Holdings (NASDAQ:PETV) s... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
Upgrades For Nektar Therapeutics (NASDAQ: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Chinook Therapeutics (NASDAQ:KDNY) shares increased by 28.75% to $15.76 during Friday's regular session. Trading volume for this security as of 12:30 EST is 1.... 
Via Benzinga
92 Biggest Movers From Friday
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the... 
Via Benzinga
64 Stocks Moving In Friday's Mid-Day Session
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Ontrak (NASDAQ:OTRK) shares rose 21.82% to $11.78 during Friday's pre-market session. The market value of their outstanding shares is at $225.5 million. As per... 
Via Benzinga
bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress
From bluebird bio, Inc.
Via Business Wire
bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row
From bluebird bio, Inc.
Via Business Wire
28 Stocks Moving in Friday's Pre-Market Session
Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 65.8% to $2.14 in pre-market trading after the company announced its ReBoot device has been granted designation as a Breakthrough... 
Via Benzinga
bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc
Via Business Wire
bluebird bio Completes Planned Business Separation
From bluebird bio, Inc.
Via Business Wire
Bluebird Bio To Withdraw Marketing Of Skysona Gene Therapy In Europe
Bluebird Bio Inc (NASDAQ: BLUE) will withdraw the regulatory marketing authorization for Skysona (elivaldogene autotemcel) in the European Union. The update comes... 
Via Benzinga
Could This Beaten-Down Biotech Stock Be the Next Buyout Target?
This gene-therapy specialist may need some help turning things around. 
Via The Motley Fool
bluebird bio Sets Record Date and Distribution Date for Planned Business Separation
From bluebird bio, Inc.
Via Business Wire
Bluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play?
These once-promising biotech stocks are trading at a fraction of their all-time highs right now. 
Via The Motley Fool
bluebird bio Provides Update on Upcoming Planned Business Separation
From bluebird bio, Inc.
Via Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
Bluebird Bio Files US Application For β-thalassemia Gene Therapy
Bluebird Bio Inc (NASDAQ: BLUE) completed the rolling submission of its marketing application to the FDA seeking approval for betibeglogene autotemcel (beti-cel)... 
Via Benzinga
Exposures Product Safety
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
2seventy bio Announces Upcoming Investor Events
From bluebird bio
Via Business Wire
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
bluebird bio Secures $75 Million in Private Placement Equity Financing
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events
From bluebird bio, Inc.
Via Business Wire
The Latest Barron's Picks And Pans Include General Electric, Netflix, Reddit And More
This weekend's Barron's reveals what market strategists recommend for a stock market that likely will struggle this fall. Other featured articles discuss biotech stocks... 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback